Bessemer Group
CPRX

Bessemer Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Bessemer Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.44M Buy
138,951
+304
+0.2% +$7.24K 0.01% 625
2025
Q4 		$3.24M Buy
138,647
+135,161
+3,877% +$3.01M 0.01% 617
2025
Q3 		$69K Buy
3,486
+2,678
+331% +$55.1K ﹤0.01% 1352
2025
Q2 		$18K Buy
808
+275
+52% +$6.49K ﹤0.01% 1595
2025
Q1 		$13K Buy
533
+100
+23% +$2.25K ﹤0.01% 1669
2024
Q4 		$9K Buy
433
+204
+89% +$4.38K ﹤0.01% 1796
2024
Q3 		$5K Buy
229
+122
+114% +$2.26K ﹤0.01% 1904
2024
Q2 		$2K Hold
107
– – ﹤0.01% 1930
2024
Q1 		$2K Hold
107
– – ﹤0.01% 1930
2023
Q4 		$2K Hold
107
– – ﹤0.01% 2012
2023
Q3 		$1K Hold
107
– – ﹤0.01% 2061
2023
Q2 		$1K Buy
+107
New +$1.54K ﹤0.01% 2134

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bessemer Group's CPRX Position: Q1 2026 in Review

Bessemer Group increased its Catalyst Pharmaceutical (CPRX) stake by 0.22% in Q1 2026, buying an estimated $7.24K and bringing the position to 138,951 shares worth $3.44M. The position accounts for 0.01% of the portfolio, ranked #625.

Bessemer Group first reported a position in CPRX in Q2 2023 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Bessemer Group held 138,951 shares of Catalyst Pharmaceutical worth $3.44M as of Q1 2026.
  • Bessemer Group bought 304 Catalyst Pharmaceutical shares in Q1 2026, an estimated $7.24K.
  • Catalyst Pharmaceutical made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #625 holding.
  • Bessemer Group first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.